Inventor · disambiguated record
Robert J. Lutz
Also filed as: LUTZ ROBERT · LUTZ ROBERT J · LUTZ ROBERT JOHN
18 granted patents·18 pending applications·407 citations·filing 1975–2024
95Inventor score
Top patents by PatentIndex Score
36 records- 0198US7557189B2Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the sameIMMUNOGEN INC·Filed 2003·Granted Jul 7, 2009·109 cites·44 claims
- 0298US7342110B2Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the sameIMMUNOGEN INC·Filed 2006·Granted Mar 11, 2008·82 cites·10 claims
- 0397US9359442B2Anti-CD33 antibodies and methods for treatment of acute myeloid leukemia using the sameIMMUNOGEN INC·Filed 2014·Granted Jun 7, 2016·29 cites·10 claims
- 0496US8119787B2Molecular tools for manufacturing anti-CD33 antibodies and fragmentsHOFFEE MARY G·Filed 2009·Granted Feb 21, 2012·21 cites·20 claims
- 0595US8337855B2Anti-CD33 antibodies and methods for treatment of acute myeloid leukemia using the sameHOFFEE MARY G·Filed 2011·Granted Dec 25, 2012·26 cites·17 claims
- 0690US8137669B2Elimination of heterogeneous or mixed cell population in tumorsGOLDMAKHER VIKTOR S·Filed 2008·Granted Mar 20, 2012·7 cites·5 claims
- 0788US8747851B2Anti-CD33 antibodies and methods for treatment of acute myeloid leukemia using the sameIMMUNOGEN INC·Filed 2012·Granted Jun 10, 2014·4 cites·7 claims
- 0888US8388960B2Elimination of heterogeneous or mixed cell population in tumorsGOLDMAKHER VIKTOR S·Filed 2011·Granted Mar 5, 2013·7 cites·3 claims
- 0985US8603483B2Anti-integrin immunoconjugates, methods and usesCHEN QIMING·Filed 2005·Granted Dec 10, 2013·8 cites·15 claims
- 1080US2024368270A1Anti-folr1 immunoconjugate regimensIMMUNOGEN INC·Filed 2024·Application pending·0 cites
- 1178US5656725APeptides and compositions which modulate apoptosisAPOPTOSIS TECHNOLOGY INC·Filed 1995·Granted Aug 12, 1997·39 cites·2 claims
- 1277US8409166B2Method for pressure mediated selective delivery of therapeutic substances and cannulaWIENER STEPHEN M·Filed 2011·Granted Apr 2, 2013·22 cites·39 claims
- 1376US3946734AApparatus for controlling the release of a drugUS GOVERNMENT·Filed 1975·Granted Mar 30, 1976·35 cites·7 claims
- 1475US8563700B2Synergistic effectsLUTZ ROBERT J·Filed 2009·Granted Oct 22, 2013·2 cites·45 claims
- 1571US2009081705A1Novel peptides and compositions which modulate apoptosisCHITTENDEN THOMAS D·Filed 2008·Application pending·0 cites
- 1671US2009291090A1Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the sameIMMUNOGEN INC·Filed 2009·Application pending·0 cites
- 1770US6221615B1Peptides and compositions which modulate apoptosisAPOPTOSIS TECHNOLOGY INC·Filed 1999·Granted Apr 24, 2001·15 cites·2 claims
- 1869US2015132323A1Anti-FOLR1 Immunoconjugate Dosing RegimensIMMUNOGEN INC·Filed 2014·Application pending·0 cites
- 1969US2008167458A1Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the sameIMMUNOGEN INC·Filed 2007·Application pending·0 cites
- 2069US2018362646A1Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the sameIMMUNOGEN INC·Filed 2018·Application pending·0 cites
- 2167US7358088B2Peptides and compositions which modulate apoptosisIMMUNOGEN INC·Filed 2006·Granted Apr 15, 2008·1 cites·6 claims
- 2267US2021155688A1Anti-folr1 immunoconjugate dosing regimensIMMUNOGEN INC·Filed 2021·Application pending·0 cites
- 2366US10000566B2Anti-CD33 antibodies and methods for treatment of acute myeloid leukemia using the sameIMMUNOGEN INC·Filed 2016·Granted Jun 19, 2018·0 cites·18 claims
- 2464US2006233814A1Elimination of heterogeneous or mixed cell population in tumorsIMMUNOGEN INC·Filed 2006·Application pending·0 cites
- 2558US2024156978A1Maytansine-antibody conjugates and methods of using sameANGIEX INC·Filed 2023·Application pending·0 cites
- 2651US2014093523A1Anti-Integrin Immunoconjugates, Methods and UsesIMMUNOGEN INC·Filed 2013·Application pending·0 cites
- 2748US7097982B2Peptides and compositions which modulate apoptosisIMMUNOGEN INC·Filed 2001·Granted Aug 29, 2006·0 cites·15 claims
- 2847US2025213711A1Anti-canag antibody conjugateIKSUDA THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 2945US2008269718A1Method for pressure mediated selective delivery of therapeutic substances and cannulaUS GOV HEALTH & HUMAN SERV·Filed 2008·Application pending·0 cites
- 3042US2012282282A1Methods for Decreasing Ocular Toxicity of Antibody Drug ConjugatesLUTZ ROBERT J·Filed 2012·Application pending·0 cites
- 3139US2017080102A1Methods for characterizing and treating acute myeloid leukemiaIMMUNOGEN INC·Filed 2015·Application pending·0 cites
- 3237US2012269827A1Compositions and Methods for Treatment of Ovarian, Peritoneal, and Fallopian Tube CancerWHITEMAN KATHLEEN R·Filed 2012·Application pending·0 cites
- 3337US2015343077A1Anti-CD37 Immunoconjugate Dosing RegimensIMMUNOGEN INC·Filed 2015·Application pending·0 cites
- 3435US2015297744A1Anti-FOLR1 Immunoconjugate Dosing RegimensIMMUNOGEN INC·Filed 2015·Application pending·0 cites
- 3535US2011177064A1Compositions and Methods for Treatment of Ovarian CancerIMMUNOGEN INC·Filed 2011·Application pending·0 cites
- 3630US5863795ANucleic acids that encode peptides which modulate apoptosisAPOPTOSIS TECHNOLOGY INC·Filed 1997·Granted Jan 26, 1999·0 cites·7 claims
Join the waitlist — get patent alerts
Get an alert when Robert J. Lutz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →